Published in Hepatitis Weekly, September 27th, 1999
The finding has vast implications for AIDS therapy, which relies heavily on nucleoside-analog reverse-transcriptase inhibitors (NARTIs). It also raises questions about the nucleoside-based drugs used or under development for the treatment of hepatitis and cancer.
John D. Schuetz and colleagues of St. Jude Children's Research Hospital, Memphis, Tennessee, observed that the human T-lymphoid cell line CEM-r1 is resistant to the potent acyclic nucleoside analog PMEA. They found that this resistance was due to the cells' ability to get rid of the drug. Analysis showed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.